ASCO: Merck touts Keytruda's 'convergent' benefits across postsurgery lung cancer patient groups

As biopharma industry watchers wait to see whether Keytruda will hit its goal as a postsurgery treatment in early lung cancer patients with high tumor expressions of the PD-L1 biomarker, Merck & Co. is rolling out new data to show the drug’s benefits across other patient groups.